Antibodies for the bioanalysis and drug monitoring of ocrelizumab

Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug ocrelizumab (Ocrevus) using our range of ready-made anti-idiotypic antibodies.

  • Inhibitory antibodies specific to ocrelizumab
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch-to-batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies specific to ocrelizumab

Specificity

Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Ocrelizumab

Inhibitory

Type 1

HCA399

AbD47395ia

hIgG1

25.6

ADA control

Order HCA399

HCA400

AbD50641ia

hIgG1

<0.001

ADA control

Order HCA400

HCA401

AbD50989ia

hIgG1

0.06

ADA control

Order HCA401

TZA044

AbD50641ad

Fab-F-Spy2-H1

<0.001

PK bridging ELISA (capture)

Order TZA044

TZA045

AbD50651ad

Fab-F-Spy2-H1

<0.001

PK bridging ELISA (detection)

Order TZA045

TZA045P

AbD50651pap

Fab2-FH-X22-HRP2

<0.001

PK bridging ELISA (detection)

Order TZA045P

* Affinity measured in the monovalent Fab format
1 Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
2 Fab2-FH-X22-HRP= Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags and Fab-SpyTag coupled to HRP conjugated BiCatcher

Anti-Ocrelizumab Inhibitory Antibodies (Type 1)

Type 1 anti-ocrelizumab antibodies inhibit the binding of the drug ocrelizumab to its target, the B cell surface marker CD20. They are ideal for the development of a pharmacokinetic (PK) bridging ELISA to measure free drug. The antibody in fully human IgG1 format is suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.

ELISA Protocols to Get You Started

PK Bridging ELISA

PK Bridging ELISA: TZA044 (capture) and TZA045P (detection)

PK Bridging ELISA: TZA044 (capture) and TZA045 (detection)

Fig. 1. Ocrelizumab PK bridging ELISA using antibodies TZA044 and TZA045P.

Fig. 1. Ocrelizumab PK bridging ELISA using antibodies TZA044 and TZA045P.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.

ADA Bridging ELISA

ADA Bridging ELISA: HCA399, HCA400, HCA401

Fig. 2. Ocrelizumab ADA bridging ELISA using antibody HCA399, HCA400, and HCA401

Fig. 2. Ocrelizumab ADA bridging ELISA using antibody HCA399, HCA400, and HCA401

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Resources

Anti-idiotypic antibodies, their binding types and properties

Anti-biotherapeutic antibody quality control and characterization

Custom anti-idiotypic antibody generation service

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.